Zobrazeno 1 - 9 of 9 pro vyhledávání: '"Gregory Harriman"'
1
Ex vivo expanded human CD4+CD25+Foxp3+ regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD)
Autor: Gregory Harriman, Allis Soto, Tinghua Cao, Li Li, Steven Charles Eck, Mindi R. Walker, Wei Zhou, Weihong Wang
Publikováno v: Cellular Immunology. 258:65-71
Mouse studies demonstrated that infusion of CD4+CD25+ regulatory T cells (Tregs) prevented graft versus host disease (GVHD) lethality after bone marrow transplantation (BMT). But the potential impact of human Tregs on GVHD has not been well demonstra
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e40aee2643c4c77d63b846b3db10c6a7
https://doi.org/10.1016/j.cellimm.2009.03.013
Zobrazit plný text záznamu
2
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis
Autor: M Weisman, Marc Feldmann, J. R. Kalden, E W St Clair, F. C. Breedveld, Daniel E. Furst, Ravinder Nath Maini, Peter E. Lipsky, Paul Emery, Josef S. Smolen, Gregory Harriman, D. van der Heijde
Publikováno v: New England Journal of Medicine. 343:1594-1602
Background: Neutralization of tumor necrosis factor α (TNF-α) for three to six months reduces the symptoms and signs of rheumatoid arthritis. However, the capacity of this approach to effect a more sustained benefit and its effect on joint damage a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ebf881855a2c44566f7689e1812d9c2f
https://doi.org/10.1056/nejm200011303432202
Zobrazit plný text záznamu
3
Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment
Autor: Gregory Harriman, Thomas F Schaible, Lesley K Harper
Publikováno v: Annals of the Rheumatic Diseases. 58:i61-i64
Cytokines play a central part in the human immune response and can generally be categorised as proinflammatory or anti-inflammatory cytokines in nature. Tumour necrosis factor α (TNFα) is a proinflammatory cytokine and is a key mediator of inflamma
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ae03b336c7a4f9fe770a1ae3021032f6
https://doi.org/10.1136/ard.58.2008.i61
Zobrazit plný text záznamu
4
Enhanced suppressive function of regulatory T cells from patients with immune-mediated diseases following successful ex vivo expansion
Autor: Tinghua Cao, Li Li, William A. Faubion, Sally E. Wenzel, Gregory Harriman
Publikováno v: Clinical immunology (Orlando, Fla.). 136(3)
Recent studies and our current data demonstrated the deficits in the numbers and/or functions of the CD4(+)CD25(+)Foxp3(+) Treg cells in the patients with autoimmune diseases, indicating that restoration of Treg cells in these patients could be a pot
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::685c8d87b489e6cdcc92181ee9604110
https://pubmed.ncbi.nlm.nih.gov/20472506
Zobrazit plný text záznamu
5
FRI0071 Responses to infliximab therapy in the attract trial assess with the disease activity score (das): clinical response measured by das at 102 weeks correlates with arrest of radiologic progression and shows higher response rate than acr20 criteria
Autor: C Antoni, A. Kavanaugh, J. R. Kalden, Gregory Harriman, T Schaible, Bernhard Manger, G Keenan, K Patel
Publikováno v: Speaker abstracts 2001.
Background In the ATTRACT trial, the anti-TNF-monoclonal antibody infliximab showed significant improvement in disease activity score (DAS), reduction in signs and symptoms, inhibition of progression of structural damage and improved quality of life
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::95535f79cf0c289f9b1c98060b40b9c7
https://doi.org/10.1136/annrheumdis-2001.1200
Zobrazit plný text záznamu
6
FRI0068 102-wk clinical and radiologic results from the attract trial: a 2 year, randomised, controlled, phase 3 trial of infliximab (remicade®) in pts with active ra despite mtx
Autor: D. van der Heijde, Josef S. Smolen, J. R. Kalden, E.C. Keystone, P Lipksy, Ravinder Nath Maini, Gregory Harriman, Paul Emery, F. C. Breedveld
Publikováno v: Speaker abstracts 2001.
Background The ATTRACT trial studied the long term efficacy and tolerability of infliximab in 428 pts with active RA despite MTX (median dose of 15 mg/wk). Objectives Methods While continuing MTX, pts were randomly assigned to one of five therapeutic
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::131c0ba6725fceb4f7a0b0c2de9a1e4e
https://doi.org/10.1136/annrheumdis-2001.1197
Zobrazit plný text záznamu
7
OP0087 Infliximab plus methotrexate inhibits structural damage, reduces sign and symptoms and improves disability in patients with active early rheumatoid arthritis
Autor: J. R. Kalden, Ravinder Nath Maini, F. C. Breedveld, Gregory Harriman, C. Han, Paul Emery, Josef S. Smolen, D. van der Heijde
Publikováno v: Speaker abstracts 2001.
Background In the ATTRACT trial, 428 pts with active RA despite methotrexate (MTX) therapy received MTX alone or infliximab at 3 mg/kg or 10 mg/kg every 4 or 8 weeks along with MTX for 102 weeks. Since joint damage may progress rapidly early in the d
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c8209a473faf9def675112dbcefda2b6
https://doi.org/10.1136/annrheumdis-2001.1217
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje